Treating Unresectable Early-Stage NSCLC

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

A disease-free survival and minimal residual disease event-free status was maintained for most patients with adjuvant osimertinib for EGFR-mutant NSCLC.

Patients with ALK-positive NSCLC not vulnerable to neurological adverse effects or prone to weight issues, might benefit from treatment with lorlatinib.